西罗莫司在肝移植术后免疫抑制中的效果及安全性

目的 探讨肝移植术后应用西罗莫司(SRL)的免疫抑制效果和安全性.方法 对21例以SRL作为免疫抑制维持治疗的肝移植受者进行了观察.其中术后直接应用SRL者6例(术前肾功能不全者2例、原发病为肿瘤者4例);因他克莫司(Tac)药物相关性因素替换为SRL者15例(Tac肾毒性4例、高度可疑Tae肝毒性8例、Tac用量过大仍不能达到预期血药浓度者3例).术后对21例受者平均随访25.4个月(6～42个月),评估SRL的临床免疫抑制效果及安全性.结果 随访期间,2例受者因药物副反应停药,药物耐受率为90.5%.发生急性排斥反应1例次,经治疗后痊愈,其余患者均获得良好的免疫抑制效果.Tac肾毒性患者肾功能改善3例;Tac肝毒性患者肝功能显著好转6例.结论 SRL作为受者肝移植术后的免疫抑制维持治疗是安全有效的.术后早期及时用SRL替换Tac可有效逆转后者所致的肝、肾毒性损害.

The efficacy and safety of sirolimus in immunosuppression after liver transplantation

ObjectiveTo evaluate the efficacy and safety of Sirolimus (SRL) in immunosuppression following liver transplantation. Methods SRL was applied in 21 patients totally.Indication for adoption was Tac-related nephrotoxicity (4/21), suspiciously Tac-related hepatoxicity (8/21), Tac overdose (3/21), renal insufficiency pre-operation (2/21), or cancer (4/21). Median follow-up was 25. 4 months. Results SRL provided an adequate prophylaxis against rejection in all study patients, with one case of acute rejection. Sirolimus was Withdrawn in 2 cases due to its sideeffect. Tat-induced hepatoxicity in 6 cases and nephrotoxicity in 3 cases were relieved significantly.Conclusions SRL given alone appears to be an effective primary immunosuppressant regimen fororthotopic liver transplantation patients. Early conversion contributes to significant improvement of Tac-related hepatoxicity and nephrotoxicity.